Cosmo Bio Co

Cosmo Bio Co CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Cosmo Bio Co (3386.T) as of Oct 27, 2026 is 38.49 %. In the previous year, CapEx to Operating Cash Flow Ratio was 89.63 % — a change of -57.06% (lower).

CapEx/OCF

38.49 %

YoY

-57.06%

Last updated:

CapEx to Operating Cash Flow Ratio of Cosmo Bio Co is 2025 38.49 % . CapEx to Operating Cash Flow Ratio of Cosmo Bio Co was 2024 89.63 % . It decreases by -57.06% lower compared to the previous year.

The Cosmo Bio Co CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
5.62 JPY
Jan 1, 2019
31.99 JPY
Jan 1, 2020
8.09 JPY
Jan 1, 2021
21.76 JPY
Jan 1, 2022
36.62 JPY
Jan 1, 2023
13.59 JPY
Jan 1, 2024
89.63 JPY
Jan 1, 2025
38.49 JPY
The Cosmo Bio Co CapEx/OCF history
YEARCapEx/OCFYoY
38.49 %-57.06%
89.63 %+559.65%
13.59 %-62.90%
36.62 %+68.29%
21.76 %+168.81%
8.09 %-74.69%
31.99 %+469.48%
5.62 %-98.96%
538.20 %+1,121.63%
44.06 %+15.98%
37.98 %+112.86%
17.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

CapEx to Operating Cash Flow Ratio of Cosmo Bio Co is 38.49 % in 2025.

CapEx to Operating Cash Flow Ratio of Cosmo Bio Co changed from 89.63 % to 38.49 %, representing a -57.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Cosmo Bio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co